|View printer-friendly version|
|June 14, 2013 8:01 a.m.|
|Teva Announces AZILECT® (Rasagiline Tablets) Data to Be Presented at the 2013 International Congress of Parkinson’s Disease and Movement Disorders|
Studies Further Define the Clinical Utility of AZILECT® in the Treatment of Parkinson’s Disease (PD)
“The AZILECT® abstract topics presented at MDS demonstrate our efforts to further clarify the clinical utility of rasagiline to prescribers and PD patients across various stages of the disease,” said
Some of the presentations include:
ABOUT AZILECT® (
AZILECT® (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.
Patients should not take AZILECT® if they are taking meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s Wort, cyclobenzaprine, or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious reaction. Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. Patients with moderate to severe liver disease should not take AZILECT®. Patients should not exceed a dose of 1 mg per day of AZILECT® in order to prevent a possibly dangerous increase in blood pressure.
Side effects seen with AZILECT® alone are flu syndrome, joint pain, depression, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.
See additional important information at http://www.azilect.com/Resources/PDFs/PrescribingInformation-pdf.aspx. For hardcopy releases, please see enclosed full prescribing information.
AZILECT® is currently available in more than 40 countries worldwide, including the U.S.,
Teva's Safe Harbor Statement under the